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Allogeneic (allo) and autologous (auto) hematopoietic cell transplantation (HCT) provide the potential to cure
otherwise fatal diseases but they are resource-intense therapies. There is scant literature describing the
burden of hospital readmission in the critical 6-month period of immunosuppression after HCT. We report
the incidence, causes, and outcomes of readmission in the 6 months after day 0 of HCT and in the 30 days
after hospital discharge. This study is an institutional review boardeapproved retrospective medical record
review of children who underwent HCT at a single institution. Between January 1, 2008 and December 31,
2011, 291 children underwent HCT at our institute. Of these, 140 patients were excluded because they were
not followed primarily at our institute for the ﬁrst 6 months after transplantation, 14 patients were excluded
because they died during their initial hospitalization, and 1 patient was excluded because the initial hospi-
talization was longer than 6 months. Of the remaining 136 patients, 63% had at least 1 readmission. Of the
patients who underwent allo-HCT, 78% were readmitted, in contrast to 38% of auto-HCT patients (P < .001).
For the 206 readmissions, the mean length of hospital stay was 10.7 days (range, 1 to 129). Seventy-two
percent of auto-HCT patients were initially readmitted for fever, and 46% ultimately had a source identi-
ﬁed. No risk factors for readmission were found in the auto-HCT group. Fifty-two percent of allo-HCT patients
were readmitted for fever and 28% of these patients ultimately had an identiﬁed source. Gastrointestinal-
related problems accounted for 30% of primary readmissions among allo-HCT patients. Patients with an
unrelated donor had a trend towards increased rates of 30-day readmission (P ¼ .06) and were more likely to
have a second readmission (P ¼ .002). Patients who were cytomegalovirus (CMV) positive before trans-
plantation were more likely to be readmitted (P ¼ .02). The majority of children who undergo HCT are
readmitted during the critical 180 days after transplantation. Readmission is much more common among
allo-HCT patients, in particular those with unrelated donors and CMV-positive serologies before trans-
plantation. Fever is the most common cause of readmission in these patients, and serious infections are
identiﬁed in a signiﬁcant portion of patients. These ﬁndings and future research in this area will help improve
both patient education and resource utilization.
 2015 American Society for Blood and Marrow Transplantation.BACKGROUND
Hematopoietic cell transplantation (HCT) provides
potentially curative therapy for many neoplastic, hemato-
logic, metabolic, and immunodeﬁciency diseases. Allogeneic
HCT (allo-HCT) andautologousHCT (auto-HCT) are associated
with signiﬁcant risk, given the high toxicity of conditioningdgments on page 919.
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ty for Blood and Marrow Transplantation.regimens and the prolonged period of immune suppression
after transplantation. There is an extensive literature
demonstrating that innate immunity, including epithelial
barriers, monocytes, granulocytes, andmacrophages, recover
within weeks; B cell and CD8 T cell function recover over a
period ofmonths; andCD4Tcell functionmay take years after
transplantation tonormalize [1,2]. The pace of recovery varies
by the type of conditioning a patient receives, donor source,
and the type of cells utilized for the transplantation. After
autologous transplantation, the pace of immune reconstitu-
tion would be expected to be more rapid given the lack of
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tions, but the speciﬁc timeline has not been clearly delineated
[3]. Neutropenia typically resolves in 14 to 21 days after
transplantation, but there are laboratory and functional
changes in the immune system for much longer [2,3]. In
allogeneic transplantations, the use of peripheral blood stem
cells hastens T cell reconstitution when compared with bone
marrow, but the risk of infection remains high for at least 1
year after HCT [4]. When umbilical cord blood is used as the
stem cell source, transplanted cells are naïve, and thus T
cellemediated cellular immunity in particular is deﬁcient for
months after transplantation [5,6]. Even as immune cell
counts recover, relative immunodeﬁciency persists as the
reconstituted T and B cell subsets likely do not hold the
breadth of antigen identiﬁcation seen in a normal immune
system. Children receiving HCT are typically discharged soon
after neutrophil engraftmentddeﬁned as an absolute
neutrophil count greater than 500 cells/high power ﬁeld for 3
consecutive daysdbut months before full immune reconsti-
tution. Thus, there is an ongoing risk of complications and
consequent readmission, which will likely vary among pa-
tient groups given the heterogeneity of the population.
Overall, 6.5% of children admitted to general children’s
hospitals are readmitted within 30 days of discharge, and the
highest rates of readmission are in children with neoplasms
[7]. Readmission rates after stem cell transplantationwould be
expected to be greater than that seen in general pediatric
oncology patientsdas high as 50% in 1 small pediatric
seriesdyet there is a paucity of data about this population [8].
Adult and pediatric patients likely have different post-
transplantation courses given the types of disease seen in
adults and the burden of comorbidities; nevertheless, this
population may provide insight into the pediatric HCT popu-
lation. Among adult patients undergoing allo-HCT, 39% were
readmitted within 30 days, most commonly for fever or
infection. Receiving total body irradiation, use of an unrelated
donor, and acquiring an infection during the index hospitali-
zation were shown to be risk factors for readmission [9].
A better understanding of the incidence, causes, and risk
factors for readmission in children undergoing HCT may
improve quality of care and outcomes. Potential initiatives
include improvement in predischarge patient education,
different approaches to prophylactic antibiotics, or use of long-
term central venous access. Additionally, such information
would inform resource allocation and identify high-risk pop-
ulations requiring close monitoring and follow-up. A study of
pediatric cardiothoracic surgery patientsdanother group
athigh riskof readmissiondshowed that aﬁrmunderstanding
of the risk factors for readmission could inform quality
improvement measures in the postoperative period [10].
In this study, we describe the incidence, causes, risk factors,
and outcomes of hospital readmission in a large pediatric HCT
program at a tertiary freestanding pediatric hospital. Read-
missions were evaluated in the critical 6 months after day 0 of
transplantation, during which time signiﬁcant immune sup-
pression persists. Given that the standard metric for assessing
readmissions after hospitalization is 30 days from discharge,
we also report 30-day readmission data.Wehypothesized that
the readmission rates would be higher among children un-
dergoing allo-HCTcomparedwith those undergoing auto-HCT,
and that graft-versus-host disease (GVHD) and complications
occurring during initial hospitalization may be risk factors for
readmission during the 180 days after transplantation.
Furthermore, we hypothesized that readmission in itself may
have prognostic impact on outcomes at 1 year.METHODS
Patients and Data Collection
This study is an institution review boardeapproved retrospective
medical record review of 291 consecutive children who underwent HCT
between January 1, 2008 and December 31, 2011 at the Dana-Farber/Boston
Children’s Hospital Cancer Center (Figure 1). Of these, 140 patients (75%,
n ¼ 106, allo-HCT; 25%, n ¼ 34, auto-HCT) were excluded because they were
not followed exclusively at the Dana-Farber for 6 months after discharge
from the primary hospital admission (index hospitalization), and 14 patients
(71%, n ¼ 10, allo-HCT; 29%, n ¼ 4, auto-HCT) were excluded because they
died during their initial hospitalization. One allo-HCT patient was hospi-
talized for more than 6 months after day 0 of hospitalization and was
consequently omitted from analysis. Hospital records were reviewed for the
remaining 136 patients from the day of admission for HCT to 6 months after
the day of transplantation. Of the 136 included patients, 65% received
allo-HCT (n ¼ 88) and 35% underwent auto-HCT (n ¼ 48). From the index
hospitalization we recorded age at transplantation, gender, underlying
disease, transplantation type (auto, allo), donor relation (related, unrelated),
time to neutrophil count > 500, presence of GVHD during initial hospitali-
zation for allo-HCT patients, presence of infection (bacterial, viral, or fungal),
whether there was an admission to the intensive care unit (ICU) after
transplantation, and whether the patient was readmitted to our hospital
within 6months after transplantation (6-month readmission) and/or within
30 days from discharge from the index hospitalization (30-day read-
mission). Patients who underwent planned tandem transplantations were
reported beginning from the date of the last transplantation. Planned
readmissions, such as those for antibody therapy or scheduled elective
surgeries, were not classiﬁed as readmissions.
All allo-HCT patients and/or donors who were IgG positive for
cytomegalovirus (CMV) before HCT were screened weekly for viral reac-
tivation by antigen testing or quantitative PCR.
In our practice, criteria for discharge after HCT include the following: (1)
neutrophil engraftment, (2) no active infections, and (3) no active GVHD.
The majority of patients are discharged with a central line. Before discharge,
all patients and their families undergo a formalized discharge teaching
session with a dedicated clinical nurse specialist, which includes discussion
of readmission criteria (fever, diarrhea, cough, etc). In addition, all patients
have nutrition consultation during HCT and at the time of discharge.
For those patients readmitted, additional information was collected,
including the number of readmissions within 6 months from the day of
transplantation (day 0), the cause of readmission, the length of readmission,
transfer to the ICU during readmission, and documented infection during
readmission.
For all patients, 100-day, 6-month, and 1-year overall mortality,
transplantation-related mortality (TRM) data, and survival data were
collected.
Statistical Analysis
The readmission rate was calculated by taking the total number of pa-
tients with at least 1 readmission in the given time period and dividing by
the 136 patients reviewed; a 95% conﬁdence interval (CI) was placed on this
rate. Risk factors for readmission, including age, positive blood culture,
transplantation type, donor type, and GVHD at time of discharge, were
analyzed with univariate Fisher’s exact test and a multivariate logistic
regression model. To assess the impact of readmission on mortality, Kaplan-
Meier curves of overall survival (OS), were plotted for all patients, by
readmission versus no readmission, and a log-rank test comparison of the
curves was performed. OS point estimates are at 1 year  standard error. OS
was calculated starting from the time of transplantation until death from
any cause or until last contact if the patient did not die. A logistic regression
model was used to test if readmission was associated with 1-year mortality.
Logistic regression models were used to assess the prognostic impact of age,
positive blood culture during readmission, and transplantation type on
second readmission, and Cox proportional hazard regression models
assessed the effect of these factors on time to second readmission. The same
methods were used to address the impact of peak fever at readmission,
positive blood culture during readmission, age and donor type on second
readmission, and time to second readmission. Cumulative incidence of TRM,
with adjustment for death from other causes, was calculated according to
the methods of Kalbﬂeish and Prentice [11].
RESULTS
Readmission Rates
For the 136 patients in our study, 41% (n ¼ 56) were
readmitted within 30 days of discharge from their primary
transplantation hospitalization; 52% (n ¼ 46) of allo-HCT
patients and 21% of auto-HCT patients (n ¼ 10) (P < .01). In
Figure 1. CONSORT diagram of the determination of the analytic cohort and their 6-month readmission status.
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(n ¼ 87) of patients had at least 1 readmission; 78% (n ¼ 69)
of the allo-HCT cohort and 38% (n ¼ 18) of auto-HCT patients
(P < .001) (Table 1). Of the 87 readmitted patients, 64%
(n ¼ 56) had a second readmission: 71% (n ¼ 49) of allo-HCT
patients and 39% (n ¼ 7) of auto-HCT patients (P ¼ .01)
(Table 1). There were a total of 206 readmissions in this
patient population over the 6 months after day 0 of trans-
plantation, with an average length of hospitalization of 10.7
days (range, 1 to 129).Table 1
Readmission Rates in Auto- and Allo-Transplantation Patients
Outcome All Patients Allo-Transplan
No. Evaluable Rate, % (95% CI) No. Evaluable
30-d readmission 56 of 136 41 (33-49) 46 of 88
6-mo readmission 87 of 136 63 (56-72) 69 of 88
Second readmission 56 of 87 64 (54-74) 49 of 69All subsequent results will be reported on readmission
data from the 6 months after day 0 of transplantation, unless
otherwise speciﬁed. Figure 1 describes the absolute numbers
of patients and readmissions reviewed in the study.
Auto-HCT Patients
Of the 48 auto-HCT patients, the average age was 8 years
(range, 6 months to 20 years) and the average length of
hospitalization after transplantation day 0 was 25 days
(range, 9 to 77). Of the 18 readmitted auto-HCT patients, thetation Auto-Transplantation
Rate, % (95% CI) No. Evaluable Rate, % (95% CI) P Value
52 (42-63) 10 of 48 21 (9-32) <.01
78 (70-87) 18 of 48 38 (24-51) <.01
71 (60-82) 7 of 18 39 (16-61) .01
Table 2
Risk Factors for Readmission in Auto- and Allo-HCT Patients
Risk Factors 30-d Readmission 6-mo Readmission
No Yes P Value* No Yes P Value*
All patients
Transplantation type
Allo 42 46 <.0001 19 69 <.0001
Auto 38 10 30 18
Age
13 yr 59 39 .70 37 61 .60
>13 yr 21 17 12 26
Positive blood culture during transplantation hospitalization
Yes 29 20 1.00 20 29 .50
No 51 36 29 58
ICU stay during transplantation hospitalization
Yes 9 9 .40 8 10 .40
No 71 47 41 77
Allo-HCT
Donor type
Related 16 9 .06 6 19 .70
Unrelated 26 37 13 50
Age
13 yr 33 30 .20 16 47 .30
>13 yr 9 16 3 22
GVHD at time of discharge
Yes 4 5 1.00 4 5 .10
No 38 41 15 64
Positive blood culture during transplantation hospitalization
Yes 15 15 .80 10 20 .06
No 27 31 9 49
CMV status
Positive 16 22 .40 4 34 .02
Negative 25 24 14 35
Equivocal 1 0 1 0
ICU stay during transplantation hospitalization
Yes 5 8 .60 4 9 .50
No 37 38 15 60
Auto-HCT
Age
13 yr 26 9 .20 21 14 .70
>13 yr 12 1 9 4
Positive blood culture during transplantation hospitalization
Yes 14 5 .50 10 9 .40
No 24 5 20 9
ICU stay during transplantation hospitalization
Yes 4 1 1.00 4 1 .60
No 34 9 26 17
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(range, 2 to 86). Seventy-two percent (n ¼ 13) presented
with fever. Forty-six percent of patients with fever (n ¼ 6)
ultimately had an identiﬁed infectious source: Staphylo-
coccus non-aureus bacteremia (n ¼ 3), Escherichia coli
bacteremia (n ¼ 1), Acinetobacter bacteremia (n ¼ 1), and
Pantoea/Shewanella bacteremia (n ¼ 1). Two patients were
admitted for identiﬁed infections without an antecedent
fever: viral stomatitis and herpes zoster. Of the 3 other
patients without fever, 1 was readmitted for vomiting, 1 for
poor weight gain, and 1 for gastric tube malfunction.
Age, admission to the ICU, and positive blood culture
during primary admission were not signiﬁcant predictors of
readmission on univariate or multivariate analysis among
auto-HCT patients (Table 2).
Of the 18 auto-HCT patients whowere readmitted, 7 had at
least 1 additional readmission, for a total of 13 second read-
missions among thispopulationandanaverageof 1.72 (range,1
to4, 95%CI,1.19 to2.26) subsequent readmissions. Therewere4
readmissions for fever: 2 patients were found to have Klebsiella
pneumoniae bacteremia and a source was not identiﬁed in the
remaining 2. One patient had a gastric tube site cellulitis
without antecedent fever. One patient had 3 subsequentreadmissions for hypertension and pericardial effusion and
1 had 3 subsequent readmissions formalnutrition. One patient
was admitted for hyperkalemia and the last for lethargy.
At 1 year after transplantation, 2 auto-HCT patients had
diedd1 from relapsed primitve neuroectodermal tumor on
day 304 after transplantation and 1 in an auto accident 101
days after transplantation for Hodgkin lymphoma. No auto-
HCT patients died of treatment-related causes.
Allo-HCT Patients
Of the 88 allo-HCT patients, the average age was 9 years
(range, 2 months to 22 years), the average length of hospi-
talization after transplantation day 0 was 39 days (range, 16
to 177), and the mean time from discharge to readmission
was 30 days (range, 2 to 127). Fifty-two percent (n ¼ 36) of
patients had a fever at time of readmission; of these, a source
was ultimately identiﬁed in 28% (n¼ 10). Of the 10 patients, 4
were bacteremic: 1 patient died of Klebsiella septic shock, the
remaining blood cultures grew Staphylococcus non-aureus,
Mycobacterium fortuitum, and Enterobacter cloacae. Five had
viral infections (2 CMV viremia, 1 CMV colitis, 1 Epstein-Barr
viremia,1 adenovirus viremia), and 1 had radiologic sinusitis.
The remaining 72% of patients who presented with fever did
not have an identiﬁed source of infection. Of the 33 patients
without fever, 11 patients were readmitted for gastrointes-
tinal (GI) problems: 1 had GI GVHD,1 had poor weight gain, 2
had dehydration, 1 was in preparation for a GI cleanout
before colonoscopy, and the remainder had vomiting and
diarrhea. There were 7 patients readmitted with infections
without antecedent fever, including 4 with CMV reactivation
detected on routine screening, 1 with orbital cellulitis, 1 with
a presumed central venous line site infection, and 1 with
sinusitis. Remaining causes of readmission were varied.
Although donor type (unrelated versus related) was not
statistically signiﬁcantly predictive of 6-month readmission,
there was a trend towards increased rates of 30-day read-
mission for patients with unrelated donors in comparison to
those with related donors (P ¼ .06). Patients who were CMV-
IgG positive before transplantation had a statistically signif-
icant higher 6-month readmission rate than patients whose
CMV status was negative or equivocal (P¼ .02). Age, GVHD at
time of discharge, and positive blood culture during index
hospitalization did not predict hospital readmission among
allo-HCT patients (Table 2).
Of the 69 allo-HCT patients who were readmitted, 49 had
at least 1 additional readmission, and the average number of
readmissions among all 69 patients was 2.54 (range, 1 to 8,
95% CI, 2.15 to 2.92). There were a total of 106 subsequent
readmissions among this population, and 45% (n ¼ 49) were
for fever, with a fever source identiﬁed in 37% (n ¼ 18). The
most commonly identiﬁed organisms were CMV (n ¼ 5),
Clostridium difﬁcile (n ¼ 3) and Staphylococcus non-aureus
bacteremia (n ¼ 3). Of the 57 nonfever second readmissions,
18 were for complaints referable to the GI system,11were for
respiratory complaints, 4 were for electrolyte abnormalities,
3 for central venous line malfunctions, and in the remaining
23, causes were varied.
Allo-HCT patients who had an unrelated donor had 6.3
(95% CI, 2.0 to 20.0) times greater odds of having second
readmissionwithin 6 months after transplantation than allo-
HCT patients who had a related donor (P ¼ .002).
At 1 year after transplantation, 7 allo-HCT patients had
died from treatment-related causes and 6 patients had died
of progressive disease. Of the 7 patients succumbing to
treatment-related causes, 2 died of multiorgan failure, 2 died
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sepsis.Overall Mortality
One-year OS was 89%  3% (n ¼ 136); 96%  3% for auto-
HCT (n ¼ 48) and 85%  4% for allo-HCT (n ¼ 88). Patients
who were not readmitted within 30 days from discharge or
within 6months of transplantation day 0 had lower all-cause
mortality. Patients readmitted within 30 days had 1-year OS
of 84%  5% compared with 92%  3% for those not read-
mitted (P ¼ .10) (Figure 2A). Patients readmitted within 6
months of transplantation had a 1-year OS of 85%  4%
compared with those who were not at 96%  3% (P ¼ .052)
(Figure 2B). Overall survival for auto-HCT was 94.1%  5.7%
and 96.6%  3.4% for patients readmitted within 6 months of
transplantation and those who were not, respectively (P ¼
.70) (Figure 2C). Allo-HCT patients who were readmitted
within 6 months had an OS of 82.3%  4.6% compared with
those who were not 94.7%  5.1% (P ¼ .20) (Figure 2D). Pa-
tients who required ICU level care during their readmission
had a 57%  12% 1-year survival compared with 92%  3% for
those not admitted to the ICU (P < .0001). Age, type of
transplantation, and positive blood culture were not found to
be signiﬁcant predictors of OS.
The overall 1-year cumulative incidence of TRM was 6.2%
2.1% (n¼136);5.2%2.5% for thosenot readmittedwithin1
month of discharge (n ¼ 80) versus 7.7%  3.7% for those
readmitted within 1 month of discharge (n ¼ 56) (P ¼ .60)Figure 2. (A) Kaplan-Meier curves of OS, starting from the time of post-transplantati
versus readmitted within 1 month of discharge (n ¼ 56) (P ¼ .10). (B) Kaplan-Meier cu
readmission within 6 months: not readmitted (n ¼ 49) versus readmitted within 6 m
auto-HCT patients, starting from the time of post-transplantation hospital discharge,
within 6 months of transplantation (n ¼ 18) (P ¼ .70). (D) Kaplan-Meier curves of O
discharge, by readmission within 6 months: not readmitted (n ¼ 19) versus readmit(Figure 3A). The 1-year cumulative incidence of TRMwas 4.2%
 2.9% for those not readmitted within 6 months of trans-
plantation (n¼ 49) versus 7.3% 2.9% for patients readmitted
within 6 months of transplantation (n ¼ 87) (P ¼ .50)
(Figure 3B).DISCUSSION
Readmission after HCT is very common in the pediatric
population, far exceeding the average readmission rates
among hospitalized general pediatric patients. At our insti-
tute, 63% of all HCT patients were readmitted at least once in
the 6 months after transplantation. Such information may
prove beneﬁcial to families preparing for transplantation as
well as at the time of discharge, in addition to informing
resource allocation for this population. We found read-
mission to be common in the ﬁrst 30 days after discharge
from transplantation. This data has not been reported pre-
viously and may be useful for future comparative quality
improvement initiatives as 30-day readmission is easy to
capture and serves as a standard metric across many dis-
eases. However, the focus of this study was readmissions in
the 6 months after day 0 of transplantation, the time of
greatest perturbation of immunologic function.
After transplantation, 38% of children receiving auto-HCT
were readmitted, whichd although signiﬁcantly lower than
for allo-HCT patientsdis still substantial. Fever was
commonly the cause of readmission. Forty-six percent of
auto-HCT patients presenting with fever ultimately hadon hospital discharge, by readmission within 30 days: not readmitted (n ¼ 80)
rves of OS, starting from the time of post-transplantation hospital discharge, by
onths of transplantation (n ¼ 87) (P ¼ .052). (C) Kaplan-Meier curves of OS in
by readmission within 6 months: not readmitted (n ¼ 30) versus readmitted
S in allo-HCT patients, starting from the time of post-transplantation hospital
ted within 6 months of transplantation (n ¼ 69) (P ¼ .20).
Figure 3. (A) Curves of the cumulative incidence of transplantation-related mortality (TRM), starting from the time of transplantation, by readmission within 30
days: not readmitted (n ¼ 80) versus readmitted within 1 month of transplantation (n ¼ 56) (P ¼ .60). (B) Curves of the cumulative incidence of transplantation-
related mortality (TRM), starting from the time of transplantation, by readmission within 6 months: not readmitted (n ¼ 49) versus readmitted within 6 months
of discharge (n ¼ 87) (P ¼ .50).
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suggesting that these patients will likely continue to require
periods of inpatient care after transplantation and that pre-
emptive antibiotic therapy is necessary. The second most
common cause of readmission was a nutritional problem.
Neither age nor factors related to the primary hospitalization
(ICU admission, bacteremia) could be identiﬁed as risk fac-
tors for the auto-HCT population.
Among allo-HCT patients, 52% were readmitted within 30
days of discharge, a rate much higher than reported in the
adult HCT literature [9]. Of the children readmitted after allo-
HCT, 52% had fever at readmission; a source was identiﬁed in
28% suggesting admission and preemptive antibiotic therapy
are essential for patients presenting with fever. GI com-
plaints were the second most common cause of readmission.
In the allogeneic setting, such complaints often warrant an
inpatient evaluation. GVHD and infectious colitis must be
distinguished from more benign causes. In addition, con-
cerns regarding absorption of oral medications and hydra-
tion status may prompt a hospital admission.
Allo-HCT patients were more likely to have a subsequent
readmission than auto-HCT patients, with an average of 2.53
readmissions. Thus, those readmitted are likely to be read-
mitted multiple times and deserve careful monitoring after
discharge form the ﬁrst readmission. Fever and infection
were themost common causes of second readmission among
allo-HCT patients. Allo-HCT patients with unrelated donors
had 6.3 times greater odds of subsequent readmissions than
those with related donors. Positive pretransplantation CMV
serologies carried increased odds of readmission in the allo-
HCT population and may be an area worth further evaluation
in terms of prophylaxis or increased surveillance.
Patients readmitted within 6 months of transplantation
day 0 had worse 1-year OS. Roughly one half of allo-HCT
deaths in our study were the result of TRM, the causes of
which were varied. We did not ﬁnd evidence to support an
association of readmission with the incidence of TRM;
however, this may be due in part to the small sample size.
Patients who were readmitted to an ICU carried signiﬁcantly
worse odds of survival at 1 year. We were limited in identi-
fying additional risk factors for death because of small
sample size and low power.
We identiﬁed nutritional and GI-related problems as a
signiﬁcant cause of readmission in our population, apotentially preventable complication of transplantation.
Such readmission could potentially be prevented through a
predischarge nutritional care model, including nutritionist
consults and nutritional discharge follow-up plan. A similar
process in patients hospitalized for asthma demonstrated
that implementation of a well-informed standardized care
plan at the time of discharge could reduce readmissions [12].
Fever was the most common cause of readmission in our
study and a challenging complaint in terms of attempting to
reduce readmissions amongHCTpatients. In our study, 46% of
auto-HCT and 28% of allo-HCT patients presenting with fever
were found to have either a bacterial infection or viremia,
supporting the notion that fever must be taken seriously in
this patient population and include hospital admission with
prophylactic antibiotics. Infectious complications after allo-
geneic transplantationareknown tobe commonandour rates
of bacteremia are comparable to other centers [13]. Further
research should focus on elucidating robust risk factors for
true infection among all children presenting with fever. For
example, there is a rich body of literature on themanagement
of febrile infantsda population in which 5% to 7% of those
with fever have a serious bacterial infectiondthat has
demonstrated safe protocols for empiric management of
these patients [14,15]. Multicenter studies may be able to
identify similar risk factors among HCT patients and provide
evidence for standardized protocols based on presenting
symptoms and laboratory data. Alternative strategies may
focus on the need to decrease fever and infections after
transplantation, potentially includingearly removal of central
venous access and/or prophylactic antibiotic regimens.
Nevertheless, patient education should continue to focus on
informing parents of the importance of recognizing fever and
seeking urgent care in such circumstances.
A limitation of our analysis is that the patient population
was limited to the subset of patients who either were
referred from outside institutions and remained local for 6
months after treatment, or to those who were initially local
to our institute. Examining readmissions for patients who
were referred for transplantation and received subsequent
follow-up elsewhere would increase the generalizability of
our results. Of note, the proportion of allogeneic trans-
plantation patients appears comparable between the
excluded population and studied population; 75% and 65%,
respectively. Given that our data represent the experience of
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signiﬁcant cross-institute variability in readmission rates,
which might elucidate best and worst practices in trans-
plantation. As this was a retrospective chart review, there is
the possibility for ascertainment bias. The sicker patients
may have been more likely to remain local after trans-
plantation, comparedwith patients in better health whomay
have traveled home for follow-up.
In summary, readmission, including subsequent read-
missions, is a common problem in pediatric stem cell
transplantation, and families and staff should be prepared for
this possibility in the time after transplantation. Ideally, we
would be able to predict those patients at high risk of read-
mission. However, at this time our data demonstrate that
allo-HCT patients are the cohort most likely to be readmitted
and that positive pretransplantation CMV titers or having an
unrelated donor may carry an increased risk of readmission
and second readmission. Given the high proportion of pa-
tients with fever who subsequently have an identiﬁed
source, fever should continue to trigger hospital readmission
and empiric antibiotics in this population. GI complaints,
including malnutrition, are another common trigger for
readmission. It may be possible to decrease readmission
rates in this group through education and outpatient support
by a nutritional team. Readmission may indicate worse OS
and, thus, warrants closer monitoring of this population.
Future efforts should focus on a multicenter study to further
examine causes and predictors of readmission.
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